13 recruiting. 13 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Recruiting 13 |
Follow Psoriasis: new trials by email Literature Review of Psoriasis trials Research Report on Psoriasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of MK-8644 in Healthy Participants and Participants With Psoriasis (MK-8644-001) MK-8644, Placebo for MK-8644 - Psoriasis, Healthy | Phase 1 | Recruiting | Merck Sharp & Dohme LLC | 132 | 2026-10-20 | 2026-10-27 |
| A Study of HL40626S Tablets in Healthy Adults HL40626S tablets, HL40626S placebo - Skin Disease, Immune System Disease | Phase 1 | Recruiting | HighsLab Therapeutics Inc. | 64 | 2026-08-05 | 2026-10-29 |
| Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease S-4321 - Autoimmune Diseases, Rheumatoid Arthritis (RA) | Phase 1 | Recruiting | Seismic Therapeutic AU Pty Ltd | 24 | 2026-06-01 | 2026-06-01 |
| A Study of HB0017 Injection in Healthy Volunteers to Evaluate Safety and Tolerability of a Single Subcutaneous Injection in Low-Body-Weight Subjects; and Pharmacokinetics at Different Subcutaneous Injection Sites at the Same Dose HB0017 Injection, HB0017 Placebo - Psoriasis, Ankylosing Spondylitis | Phase 1 | Recruiting | Huabo Biopharm Co., Ltd. | 90 | 2026-01-19 | 2026-11-06 |
| A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults Bimekizumab regimen 1 iv, Bimekizumab regimen 2 iv, Bimekizumab regimen 3 sc - Psoriatic Arthritis, Axial Spondyloarthritis | Phase 1 | Recruiting | UCB Biopharma SRL | 392 | 2025-12-10 | 2026-11-06 |
| Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-approved Skyrizi®, and US-licensed Skyrizi® in Healthy Adult Participants SKYRIZI, CKD-704 - Psoriasis | Phase 1 | Recruiting | Chong Kun Dang Pharmaceutical | 213 | 2025-11-26 | 2025-12-19 |
| A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab) Bimekizumab - Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis | Phase 1 | Recruiting | UCB Biopharma SRL | 20 | 2025-11-05 | 2026-09-18 |
| Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis LPX-TI641, Placebo - Atopic Dermatitis (AD), Psoriasis (PsO) | Phase 1 | Recruiting | LAPIX Therapeutics Inc. | 48 | 2025-06-15 | 2025-12-19 |
| Evaluate the Safety and Pharmacokinetics/Pharmacodynamics and Food Effect of HS-20118 HS-20118 - Psoriasis | Phase 1 | Recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 142 | 2025-05-16 | 2025-06-24 |
| Quantitative Fluorescence Molecular Imaging of Ustekinumab-800CW to Elucidate the Drug Distribution Throughout Inflamed Tissue in Crohn's Disease and Psoriasis. Ustekinumab - Psoriasis, Crohn Disease | Phase 1 | Recruiting | University Medical Center Groningen | 56 | 2025-01-06 | 2025-01-15 |
| To Evaluate the Pharmacokinetics of Hemay005 Tablets in Subjects With Liver Damage Hemay005 - Psoriasis | Phase 1 | Recruiting | Ganzhou Hemay Pharmaceutical Co., Ltd | 24 | 2024-04-28 | 2025-12-04 |
| Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques SFA002 - Psoriasis | Phase 1 | Recruiting | SFA Therapeutics | 90 | 2022-03-31 | 2025-01-09 |
| Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO Biospecimen Collection, Cabozantinib, Fluoropyrimidine - Autoimmune Disease, Crohn Disease | Phase 1 | Recruiting | National Cancer Institute (NCI) | 300 | 2019-07-16 | 2026-10-05 |
Arthritis, Psoriatic (4) · Arthritis, Rheumatoid (2) · Autoimmune Diseases (2) · Axial Spondyloarthritis (2) · Crohn Disease (2) · Dermatitis, Atopic (2) · Colitis, Ulcerative (1) · Dermatomyositis (1) · Hematologic Neoplasms (1) · Hidradenitis Suppurativa (1) · Immune System Diseases (1) · Inflammatory Bowel Diseases (1) · Lupus Erythematosus, Cutaneous (1) · Lupus Erythematosus, Systemic (1)
Skin and Connective Tissue Diseases (13) · Skin Diseases (12) · Skin Diseases, Papulosquamous (12) · Arthritis (5) · Bone Diseases (5) · Joint Diseases (5) · Musculoskeletal Diseases (5) · Spinal Diseases (5) · Spondylarthritis (5) · Spondylarthropathies (5) · Spondylitis (5) · Ankylosis (3) · Immune System Diseases (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Connective Tissue Diseases (2)
CTLA-4 Antigen (1) · Hemay005 (1) · Ipilimumab (1) · Nivolumab (1) · Platinum Compounds (1) · Specimen Handling (1) · Ustekinumab (1) · bimekizumab (1) · cabozantinib (1) · risankizumab (1)
UCB Biopharma SRL (2) · Chong Kun Dang Pharmaceutical (1) · Ganzhou Hemay Pharmaceutical Co., Ltd (1) · HighsLab Therapeutics Inc. (1) · Huabo Biopharm Co., Ltd. (1) · Jiangsu Hansoh Pharmaceutical Co., Ltd. (1) · LAPIX Therapeutics Inc. (1) · Merck Sharp & Dohme LLC (1) · National Cancer Institute (NCI) (1) · SFA Therapeutics (1) · Seismic Therapeutic AU Pty Ltd (1) · University Medical Center Groningen (1)
United States (5) · Australia (3) · China (3) · Canada (2) · Germany (2) · Poland (2) · Bulgaria (1) · Czechia (1) · Jordan (1) · Netherlands (1) · Slovakia (1) · Spain (1) · Switzerland (1)
Hussein A Tawbi (1) · Jennifer Martin, MD (1) · Weiyong Li (1) · Ying Wang, PhD (1)
2025 (2), UM1CA186688 (1)